Oral candidiasis and HIV disease
... function should be checked closely, particularly with ketoconazole. Intravenous amphotericin B may pose serious side effects, including kidney toxicity. The most common side effects are fever, shaking, chills, altered blood pressure, nausea, vomiting and headache. These reactions are ...
... function should be checked closely, particularly with ketoconazole. Intravenous amphotericin B may pose serious side effects, including kidney toxicity. The most common side effects are fever, shaking, chills, altered blood pressure, nausea, vomiting and headache. These reactions are ...
PRODUCT INFORMATION Roxithromycin
... After administration of a single oral dose of Roxithromycin-GA 150mg to healthy male and female adults, the mean peak plasma concentration was 6.58 mg/L and the AUC was 94.98 mg.hour/L After administration of a single oral dose of Roxithromycin-GA 300mg to healthy male and female adults, the mean p ...
... After administration of a single oral dose of Roxithromycin-GA 150mg to healthy male and female adults, the mean peak plasma concentration was 6.58 mg/L and the AUC was 94.98 mg.hour/L After administration of a single oral dose of Roxithromycin-GA 300mg to healthy male and female adults, the mean p ...
Sinarest Levo Syrup
... In vitro studies have revealed that levocetirizine has an affinity for the human H1- receptor that is 2-fold higher than that of cetirizine. Levocetirizine dissociates from H1-receptors with a halflife of 115±38 minutes. Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dos ...
... In vitro studies have revealed that levocetirizine has an affinity for the human H1- receptor that is 2-fold higher than that of cetirizine. Levocetirizine dissociates from H1-receptors with a halflife of 115±38 minutes. Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dos ...
N
... The first study Consisted of 35 peaiRIric patients trqrA with 20 aq'lliWAM (mothrinsim deny dose 500 mg) far 3 days of whom 3e patients were avrhuM for d~macoldneffice. ...
... The first study Consisted of 35 peaiRIric patients trqrA with 20 aq'lliWAM (mothrinsim deny dose 500 mg) far 3 days of whom 3e patients were avrhuM for d~macoldneffice. ...
LOCAL ANESTHETICS,IV SEDATION AND PAIN MANAGEMENT
... • Pharmacology: Onset of action 2 to 5 min. Duration of action 4-5 hrs. • Indication:Analgesia, induction of anesthesia. • Contraindication: • Hypersensitivity, MAO inhibitors within 14 days (hpertensive crises, tachyarrethmias). Dosage: 0.1-0.2 mg/kg IV/IM/SC q3h. ...
... • Pharmacology: Onset of action 2 to 5 min. Duration of action 4-5 hrs. • Indication:Analgesia, induction of anesthesia. • Contraindication: • Hypersensitivity, MAO inhibitors within 14 days (hpertensive crises, tachyarrethmias). Dosage: 0.1-0.2 mg/kg IV/IM/SC q3h. ...
Dawn Krauskopf
... RN Indications – Give while patient is sitting up or standing (never in recumbent position) to prevent drug– induced esophagitis. Some patients find it difficult to swallow the large sized KCl tablet. Do not crush or allow to chew any potassium salt tablets. Observe to make sure patient does not suc ...
... RN Indications – Give while patient is sitting up or standing (never in recumbent position) to prevent drug– induced esophagitis. Some patients find it difficult to swallow the large sized KCl tablet. Do not crush or allow to chew any potassium salt tablets. Observe to make sure patient does not suc ...
1100_Jacob Koruth - New Cardiovascular Horizons
... • Slows conduction in fast response tissue • Dose 450-900 mg/day divided BID or TID • Hepatic metabolism and renal clearance ...
... • Slows conduction in fast response tissue • Dose 450-900 mg/day divided BID or TID • Hepatic metabolism and renal clearance ...
Xalatan - Pharmaline
... Additional mutagenicity studies on in vitro/in vivo unscheduled DNA synthesis in rats were negative and indicate that latanoprost does not have mutagenic potency. ...
... Additional mutagenicity studies on in vitro/in vivo unscheduled DNA synthesis in rats were negative and indicate that latanoprost does not have mutagenic potency. ...
Treating hot flushes: An alternative to hormonal replacement therapy
... It should not replace the official product information. Recent concerns about hormone treatments for menopause symptoms (HRT) have led to increased interest in non-hormonal therapies. Before starting any treatment, please tell your ...
... It should not replace the official product information. Recent concerns about hormone treatments for menopause symptoms (HRT) have led to increased interest in non-hormonal therapies. Before starting any treatment, please tell your ...
Review: New oral anticoagulants reduced stroke and systemic
... the new anticoagulants during bleeding events, although dabigatran may be dialyzable and prothrombin complex concentrates to reverse apixaban and rivaroxaban are being evaluated. Individualized drug selection is important and can be achieved by using risk stratification schemes for thrombosis (CHA ...
... the new anticoagulants during bleeding events, although dabigatran may be dialyzable and prothrombin complex concentrates to reverse apixaban and rivaroxaban are being evaluated. Individualized drug selection is important and can be achieved by using risk stratification schemes for thrombosis (CHA ...
Uptravi
... • No difference in mortality between groups • Addition of selexipag to baseline regimen of two meds gave benefits consistent with overall treatment effect • Similar efficacy regardless of dose range Sitbon O, et al. N Engl J Med. 2015;373(26):2522-33. ...
... • No difference in mortality between groups • Addition of selexipag to baseline regimen of two meds gave benefits consistent with overall treatment effect • Similar efficacy regardless of dose range Sitbon O, et al. N Engl J Med. 2015;373(26):2522-33. ...
Background Methods Results B. Hauns1, A. Mais1, R
... 19 patients were evaluated individually and in a descriptive manner. Overall analyses for each of the escalating dose cohorts were performed. As patient #19 dropped out from the study at an early stage, only ECG measurements of the first two study days were available. Therefore, this patient was not ...
... 19 patients were evaluated individually and in a descriptive manner. Overall analyses for each of the escalating dose cohorts were performed. As patient #19 dropped out from the study at an early stage, only ECG measurements of the first two study days were available. Therefore, this patient was not ...
Package Insert
... Finasteride is a synthetic 4-azasteroid compound. Finasteride inhibits an intracellular enzyme, Type II 5alpha-reductase, which metabolises testosterone into the more potent androgen dihydrotestosterone (DHT). Finasteride does not bind to the androgen receptor. The enlargement of the prostate gland ...
... Finasteride is a synthetic 4-azasteroid compound. Finasteride inhibits an intracellular enzyme, Type II 5alpha-reductase, which metabolises testosterone into the more potent androgen dihydrotestosterone (DHT). Finasteride does not bind to the androgen receptor. The enlargement of the prostate gland ...
Management of overdose and poisoning
... Fluid overload that prevents the administration of sodium bicarbonate A plasma salicylate concentration >100 mg/dL (7.2 mmol/L) Clinical deterioration despite aggressive and appropriate supportive care ...
... Fluid overload that prevents the administration of sodium bicarbonate A plasma salicylate concentration >100 mg/dL (7.2 mmol/L) Clinical deterioration despite aggressive and appropriate supportive care ...
Children’s Advil Suspension Ibuprofen 100 mg (NSAID) per 5 mL Drug Facts
... ■ has bloody or black stools ■ has stomach pain that does not get better ■ the child does not get any relief within first day (24 hours) of treatment ■ fever or pain gets worse or lasts more than 3 days ■ redness or swelling is present in the painful area ■ any new symptoms appear Keep out of reach ...
... ■ has bloody or black stools ■ has stomach pain that does not get better ■ the child does not get any relief within first day (24 hours) of treatment ■ fever or pain gets worse or lasts more than 3 days ■ redness or swelling is present in the painful area ■ any new symptoms appear Keep out of reach ...
Diapositive 1
... 0.5 mg/kg) of JMV 1843 as a single oral administration of an aqueous solution in comparison to a placebo ...
... 0.5 mg/kg) of JMV 1843 as a single oral administration of an aqueous solution in comparison to a placebo ...
valproates - DavisPlus
... Monitor hepatic function (LDH, AST, ALT, and bilirubin) and serum ammonia concentrations prior to and periodically during therapy. May cause hepatotoxicity; monitor closely, especially during initial 6 mo of therapy; fatalities have occurred. Therapy should be discontinued if hyperammonemia occurs. ...
... Monitor hepatic function (LDH, AST, ALT, and bilirubin) and serum ammonia concentrations prior to and periodically during therapy. May cause hepatotoxicity; monitor closely, especially during initial 6 mo of therapy; fatalities have occurred. Therapy should be discontinued if hyperammonemia occurs. ...
Cardiovascular Drug Agents
... increasing the effective refractory period. They are used for both atrial and ventricular arrhythmias. All these agents have low therapeutic toxic ratios and may produce severe adverse reactions. Cinchonism is commonly produced by drugs that are cinchona derivatives, such as Quinidine and quinine. T ...
... increasing the effective refractory period. They are used for both atrial and ventricular arrhythmias. All these agents have low therapeutic toxic ratios and may produce severe adverse reactions. Cinchonism is commonly produced by drugs that are cinchona derivatives, such as Quinidine and quinine. T ...
A Year in Review: Top New Drugs for 2010
... due to the risk of bleeding; consider longer times for patients undergoing major surgery, spinal puncture, or insertion of a spinal or epidural catheter or port. If surgery cannot be delayed, the risk of bleeding is elevated; weigh risk of bleeding with urgency of procedure. Bleeding risk can be ass ...
... due to the risk of bleeding; consider longer times for patients undergoing major surgery, spinal puncture, or insertion of a spinal or epidural catheter or port. If surgery cannot be delayed, the risk of bleeding is elevated; weigh risk of bleeding with urgency of procedure. Bleeding risk can be ass ...
Spanish Menopause Society position statement: use of tibolone in
... this drug is currently approved for the treatment of postmenopausal women in more than 70 countries. Although the effectiveness of tibolone in alleviating hot flushes seems similar to that of low-dose hormone therapy (HT), its specific pharmacological profile adds some advantage over other HTs in wo ...
... this drug is currently approved for the treatment of postmenopausal women in more than 70 countries. Although the effectiveness of tibolone in alleviating hot flushes seems similar to that of low-dose hormone therapy (HT), its specific pharmacological profile adds some advantage over other HTs in wo ...
Update on novel anticoagulants
... PT is elevated and may be useful in monitoring aPTT is prolonged There is no reliable correlation between elevation of these values and therapeutic effect ...
... PT is elevated and may be useful in monitoring aPTT is prolonged There is no reliable correlation between elevation of these values and therapeutic effect ...
Colloids
... • Refers the the proportion of molecules that are hydroxyethylated at the C2 vs he C6 position. • A higher C2:C6 ratio results in longer intravascular half life. ...
... • Refers the the proportion of molecules that are hydroxyethylated at the C2 vs he C6 position. • A higher C2:C6 ratio results in longer intravascular half life. ...
summary of product characteristics 1. name of the medicinal
... In most patients it is not necessary to withdraw beta-adrenoceptor blocking drugs prior to surgery. However, caution must be exercised when using anaesthetic agents with Co-Tenidone. The anaesthetist should be informed and the choice of anaesthetic should be an agent with as little negative inotropi ...
... In most patients it is not necessary to withdraw beta-adrenoceptor blocking drugs prior to surgery. However, caution must be exercised when using anaesthetic agents with Co-Tenidone. The anaesthetist should be informed and the choice of anaesthetic should be an agent with as little negative inotropi ...
Anticoagulation Antidote Guide
... Consider off label use of KCentra for life threatening bleeds (max dose 5000 units) Not removed by HD NOTES: PCC may partially correct PT/aPTT but will not affect anti-factor Xa activity or increase drug clearance, correlation with reduction in bleeding is unknown If ingested within 2 hours, a ...
... Consider off label use of KCentra for life threatening bleeds (max dose 5000 units) Not removed by HD NOTES: PCC may partially correct PT/aPTT but will not affect anti-factor Xa activity or increase drug clearance, correlation with reduction in bleeding is unknown If ingested within 2 hours, a ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.